Cargando…

Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome

Introduction. Primary Sjögren's syndrome (pSS) is an autoimmune epithelitis. Pulmonary arterial hypertension (PAH) is an important and severe complication, which is encountered in many collagen tissue disorders. Early diagnostic strategies are required to define it at the asymptomatic stage. Do...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobak, Senol, Kalkan, Sezai, Kirilmaz, Bahadır, Orman, Mehmet, Ercan, Ertuğurul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912822/
https://www.ncbi.nlm.nih.gov/pubmed/24511390
http://dx.doi.org/10.1155/2014/710401
_version_ 1782302142985404416
author Kobak, Senol
Kalkan, Sezai
Kirilmaz, Bahadır
Orman, Mehmet
Ercan, Ertuğurul
author_facet Kobak, Senol
Kalkan, Sezai
Kirilmaz, Bahadır
Orman, Mehmet
Ercan, Ertuğurul
author_sort Kobak, Senol
collection PubMed
description Introduction. Primary Sjögren's syndrome (pSS) is an autoimmune epithelitis. Pulmonary arterial hypertension (PAH) is an important and severe complication, which is encountered in many collagen tissue disorders. Early diagnostic strategies are required to define it at the asymptomatic stage. Doppler echocardiography is an important, noninvasive screening test for PAH diagnosis. Objective. The aim of this present study is to define the frequency of PAH in patients with pSS and to reveal correlations with laboratory and clinical findings. Material and Methods. A total of 47 patients, who were diagnosed with pSS according to American-European Study Group criteria were enrolled in the study. After all patients were evaluated clinically and by laboratory tests, Doppler echocardiography was performed in the cardiology outpatient clinic. Systolic pulmonary artery pressure (SPAP) >30 mm Hg values, which were measured at the resting state, were accepted as significant for PAH. Results. Forty-seven patients with pSS were included in the study. The mean age of patients was 48 years and the mean disease duration was 5.3 years. PAH was defined in 11 of the 47 patients (23.4%). The SPAP value was over 35 mm Hg in 5 out of 11 patients, whereas six patients had SPAP measuring 30–35 mm Hg. While pulmonary hypertension was related with earlier age and shorter duration of disease (P = 0.04), there was no statistically significant correlation between SPAP increase and clinical findings (P > 0.05). Conclusion. We have defined high PAH frequency in patients with pSS. Since there are different data in the literature, it is obvious that large scale, multicentre studies are required.
format Online
Article
Text
id pubmed-3912822
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39128222014-02-09 Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome Kobak, Senol Kalkan, Sezai Kirilmaz, Bahadır Orman, Mehmet Ercan, Ertuğurul Autoimmune Dis Clinical Study Introduction. Primary Sjögren's syndrome (pSS) is an autoimmune epithelitis. Pulmonary arterial hypertension (PAH) is an important and severe complication, which is encountered in many collagen tissue disorders. Early diagnostic strategies are required to define it at the asymptomatic stage. Doppler echocardiography is an important, noninvasive screening test for PAH diagnosis. Objective. The aim of this present study is to define the frequency of PAH in patients with pSS and to reveal correlations with laboratory and clinical findings. Material and Methods. A total of 47 patients, who were diagnosed with pSS according to American-European Study Group criteria were enrolled in the study. After all patients were evaluated clinically and by laboratory tests, Doppler echocardiography was performed in the cardiology outpatient clinic. Systolic pulmonary artery pressure (SPAP) >30 mm Hg values, which were measured at the resting state, were accepted as significant for PAH. Results. Forty-seven patients with pSS were included in the study. The mean age of patients was 48 years and the mean disease duration was 5.3 years. PAH was defined in 11 of the 47 patients (23.4%). The SPAP value was over 35 mm Hg in 5 out of 11 patients, whereas six patients had SPAP measuring 30–35 mm Hg. While pulmonary hypertension was related with earlier age and shorter duration of disease (P = 0.04), there was no statistically significant correlation between SPAP increase and clinical findings (P > 0.05). Conclusion. We have defined high PAH frequency in patients with pSS. Since there are different data in the literature, it is obvious that large scale, multicentre studies are required. Hindawi Publishing Corporation 2014 2014-01-09 /pmc/articles/PMC3912822/ /pubmed/24511390 http://dx.doi.org/10.1155/2014/710401 Text en Copyright © 2014 Senol Kobak et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Kobak, Senol
Kalkan, Sezai
Kirilmaz, Bahadır
Orman, Mehmet
Ercan, Ertuğurul
Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome
title Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome
title_full Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome
title_fullStr Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome
title_full_unstemmed Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome
title_short Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome
title_sort pulmonary arterial hypertension in patients with primary sjögren's syndrome
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912822/
https://www.ncbi.nlm.nih.gov/pubmed/24511390
http://dx.doi.org/10.1155/2014/710401
work_keys_str_mv AT kobaksenol pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome
AT kalkansezai pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome
AT kirilmazbahadır pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome
AT ormanmehmet pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome
AT ercanertugurul pulmonaryarterialhypertensioninpatientswithprimarysjogrenssyndrome